See also this year's filing and all EDGAR filings for this company.
PDF Report 0001566044_2018_VYNE_Therapeutics_Inc.pdf
Logs
| warning | The EntityCommonStockSharesOutstanding does not exist | industry.us_generic | {} |
Graph
Absolute values for 0001566044, VYNE Therapeutics Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 63,861,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 28,000 |
| 3 | remainder_Assets | 2,978,000 |
| 4 | LiabilitiesCurrent | 7,817,000 |
| 5 | LiabilitiesNoncurrent | 22,000 |
| 6 | remainder_Liabilities | 6,735,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 5,168,000 |
| 9 | ResearchAndDevelopmentExpense | 29,007,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 5,099,000 |
| 13 | remainder_ComprehensiveNetIncome | -25,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 66,867,000 |
| 1 | Liabilities | 14,574,000 |
| 2 | Expenses | 34,175,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 52,293,000 |
| 5 | NetIncome | -29,076,000 |
| 6 | ComprehensiveNetIncome | -29,088,500 |
| 7 | BaseVar | 60,370,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 2.09 |
| 9 | EconomicCapitalRatio | 3.08 |
Edgar->Model Mapping
Feature Distribution
